PharmGKB: The pharmacogenomics knowledge base

Methods in Molecular Biology

Volumn 1015, Issue , 2013, Pages 311-320

  Thorn, Caroline F ^a   Klein, Teri E ^b   Altman, Russ B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Database; Genotype; Pathways; Pharmacogenes; Pharmacogenetics; Pharmacogenomics; PharmGKB; Phenotype; VIP genes

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FIRTECAN; FIRTECAN GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2;

ARTICLE; CELL MEMBRANE; CLINICAL DECISION MAKING; DRUG METABOLISM; DRUG RESPONSE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MOLECULAR BIOLOGY; NEUTROPENIA; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALGORITHMS; DATABASES, GENETIC; HUMANS; INTERNET; KNOWLEDGE BASES; PHARMACOGENETICS;

EID: 84880383420     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-435-7_20     Document Type: Article

References (37)

1. NIH. Goals for the PGRN. http://www. nigms.nih.gov/Research/ FeaturedPrograms/PGRN/
2. Altman RB, Klein TE (2002) Challenges for biomedical informatics and pharmacogenomics. Annu Rev Pharmacol Toxicol 42:113-133
3. Povey S et al (2001) The HUGO Gene Nomenclature Committee (HGNC). Hum Genet 109:678-680
4. Wishart DS et al (2006) DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668-D672
5. Eichelbaum M et al (2009) New feature: Pathways and important genes from PharmGKB. Pharmacogenet Genomics 19:403
6. Sangkuhl K et al (2008) PharmGKB: Understanding the effects of individual genetic variants. Drug Metab Rev 40:539-551
7. Relling MV, Klein TE (2011) CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89:464-467
8. Swen JJ et al (2011) Pharmacogenetics: From bench to byte-an update of guidelines. Clin Pharmacol Ther 89:662-673
9. Bolton E, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: Integrated platform of small molecules and biological activities. In: Annual Reports in Computational Chemistry. American Chemical Society, Washington, DC
10. (US), N. L. o. M. MeSH Browser http://www.nlm.nih.gov/mesh/MBrowser.html
11. Organisation, I. H. T. S. D. SNOMED CT http://www.ihtsdo.org/snomed-ct/
12. Rubin DL et al (2005) A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge. J Am Med Inform Assoc 12:121-129
13. Altman RB et al (2003) Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13:3-5
14. Garten Y, Altman RB (2009) Pharmspresso: A text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinformatics 10(Suppl 2):S6
15. Coulet A et al (2010) Using text to build semantic networks for pharmacogenomics. J Biomed Inform 43:1009-1019
16. Chen J et al (2010) Interethnic comparisons of important pharmacology genes using SNP databases: Potential application to drug regulatory assessments. Pharmacogenomics 11: 1077-1094
17. Sissung TM et al (2010) Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform. Pharmacogenomics 11: 89-103
18. Gamazon ER et al (2009) A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics 19: 829-832
19. Feng J et al (2010) Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual's drug responses. Pharmacogenomics 11:1403-1425
20. Demir E et al (2010) The BioPAX community standard for pathway data sharing. Nat Biotechnol 28:935-942
21. Desta Z et al (2009) Antiestrogen pathway (aromatase inhibitor). Pharmacogenet Genomics 19:554-555
22. Thorn CF, Klein TE, Altman RB (2009) Codeine and morphine pathway. Pharmacogenet Genomics 19:556-558
23. Yang J et al (2009) Etoposide pathway. Pharmacogenet Genomics 19:552-553
24. Marsh S et al (2009) Platinum pathway. Pharmacogenet Genomics 19:563-564
25. Sangkuhl K, Klein TE, Altman RB (2009) Selective serotonin reuptake inhibitors pathway. Pharmacogenet Genomics 19:907-909
26. Zaza G et al (2010) Thiopurine pathway. Pharmacogenet Genomics 20:573-574
27. Gong L, Altman RB, Klein TE (2011) Bisphosphonates pathway. Pharmacogenet Genomics 21:50-53
28. Maitland ML et al (2010) Vascular endothelial growth factor pathway. Pharmacogenet Genomics 20:346-349
29. Sangkuhl K, Klein TE, Altman RB (2010) Clopidogrel pathway. Pharmacogenet Genomics 20:463-465
30. Sangkuhl K et al (2011) Platelet aggregation pathway. Pharmacogenet Genomics 21(8): 516-521
31. Oshiro C et al (2009) Taxane Pathway. Pharmacogenet Genomics 19:979-983
32. Mikkelsen TS et al (2011) PharmGKB summary: Methotrexate pathway. Pharmacogenet Genomics 21(10):679-686
33. Sangkuhl K, Klein TE, Altman RB (2011) PharmGKB summary: Citalopram pharmacokinetics pathway. Pharmacogenet Genomics 21(11):769-772
34. Thorn CF et al (2011) Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics 21(7):440-446
35. Thorn CF et al (2011) PharmGKB summary: Fl uoropyrimidine pathways. Pharmacogenet Genomics 21:237-242
36. Sim SC, Altman RB, Ingelman-Sundberg M (2011) Databases in the area of pharmacogenetics. Hum Mutat 32:526-531
37. Thorn CF, Klein TE, Altman RB (2010) Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics 11: 501-505 General Medical Sciences